ArticleJournal of the American Heart Association2025
Relations of Artificial Intelligence Vascular Age With Cardiometabolic Disease Progression: The Framingham Heart Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAortic stiffening increases pulsatile power transmission into the microvasculature, resulting in blunted microvascular reactivity, which can impair postprandial nutrient processing and glucose homeostasis. Cardiometabolic disease (CMD) contributes to aortic stiffening and risk for major cardiovascular disease events. Our goal was to assess potential bidirectional relations of aortic stiffness with CMD progression.
methodsRelations of artificial intelligence vascular age (AI-VA), a measure of aortic stiffness, with new-onset hypertension, diabetes, obesity, and lipid abnormalities were assessed in 7188 Framingham Heart Study (FHS) participants by using Cox proportional hazards regression. Short-term bidirectional relations of AI-VA with key continuous cardiometabolic measures were assessed by using autoregressive cross-lagged panel models at 2 visits 6 years apart. Progression to CMD and cardiovascular disease states was visualized using multistate transition analysis.
resultsIn models adjusted for standard vascular risk factors, accelerated AI-VA was associated with elevated risk for incident hypertension (hazard ratio [HR], 1.44 [95% CI, 1.24-1.61]), diabetes (HR 1.29 [95% CI, 1.07-1.56]), lipid abnormalities (HR 1.13 [95% CI, 1.00-1.28]), and obesity (HR 1.23 [95% CI, 1.06-1.42]). Autoregressive cross-lagged panel models demonstrated bidirectional relations between AI-VA and fasting blood glucose, triglycerides, and mean arterial pressure consistent with a self-reinforcing cycle of CMD progression. Multistate transition analysis demonstrated that most cardiovascular disease events (70%) occurred in participants who had developed at least 2 CMD states.
conclusionsIn our community-based sample with repeated measures, AI-VA, a measure of aortic stiffness, had bidirectional relations with continuous cardiometabolic measures and incident CMD, highlighting the potential utility of AI-VA as a novel screening tool for CMD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.